The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis-Reference-Cited by-同舟云学术

The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis

Published:2014-02-27 Issue:2 Volume:9 Page:e89442
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lv Qianwen,Yin Yufeng,Li Xin,Shan Guangliang,Wu Xiangni,Liang Di,Li Yongzhe,Zhang Xuan

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Rheumatoid Arthritis;ED Harris;New England Journal of Medicine,1990

2. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis;BJ Radovits;Ann Rheum Dis,2009

3. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register;LE Kristensen;Rheumatology (Oxford),2008

4. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response;LJ Gibbons;BioDrugs,2009

5. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis;GJ Pruijn;Arthritis Research & Therapy,2010

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs;Drugs;2024-07-01

2. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials;Rheumatology;2024-02-16

3. Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg;Arthritis Research & Therapy;2024-02-08

4. Baseline ANA and Anti‐Ro60/SSA Antibody as Potential Predictors for Immunogenicity and Poor EULAR Response in Adalimumab‐Treated RA Patients;Journal of Clinical Pharmacy and Therapeutics;2024-01

5. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry;Rheumatology and Therapy;2023-06-22